Skip to content

Deep Learning Radiomics Model for Predicting Post-cystectomy Outcome in Muscle Invasive Bladder Cancer

Deep Learning Radiomics Model for Predicting Post-cystectomy Outcome From Preoperative CT in Muscle Invasive Bladder Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06092450
Enrollment
500
Registered
2023-10-23
Start date
2023-08-01
Completion date
2025-06-01
Last updated
2025-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Keywords

Tomography, X-ray computed, Muscle-invasive bladder cancer, Radiomics, Deep Learning

Brief summary

Muscle invasive bladder cancer (MIBC) has a poor prognosis even after radical cystectomy. Postoperative survival stratification based on radiomics and deep learning may be useful for treatment decisions to improve prognosis. This study was aimed to develop and validate a deep learning radiomics model based on preoperative enhanced CT to predict postoperative survival in MIBC.

Interventions

OTHERdevelop and validate a deep learning radiomics model based on preoperative enhanced CT image

develop and validate a deep learning radiomics model based on preoperative enhanced CT to predict postoperative survival in MIBC

Sponsors

First Affiliated Hospital of Chongqing Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* patients with pathologically confirmed MIBC after radical cystectomy; * contrast-CT scan less than two weeks before surgery; * complete CT image data and clinical data.

Exclusion criteria

* patients who received neoadjuvant therapy; * non-urothelial carcinoma; * poor quality of CT images; * incomplete clinical and follow-up data.

Design outcomes

Primary

MeasureTime frameDescription
Overall survival(OS)up to 10 yearsthe time from the date of surgery to death from any cause or the date of last contact (censored observation) at the date of data cut-off.
Recurrence free survival(RFS)up to 10 yearsthe time from the date of surgery to the date of first documented disease recurrence. Patients without recurrence at the time of analysis will be censored.

Countries

China

Contacts

Primary ContactZongjie Wei
wzj9846@163.com023-89012557

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026